companies / ugen-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-02 json
| total_raised | 163,043,971163.0M | ○ |
|---|---|---|
| founded | null | |
| hq | St. Louis, Missouri | |
| industry | unknown | |
| stage | null |
Wugen is a clinical-stage biotech developing off-the-shelf allogeneic cell therapies for hard-to-treat blood and solid tumors. Its programs target patients with cancers such as relapsed or refractory acute myeloid leukemia and T-cell malignancies. The company's Moneta platform engineers cytokine-induced memory natural-killer cells designed to be more durable and potent than conventional NK therapies.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-09-08 | Funding round | 163,043,971163.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Funding round, $163.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $163.0M, 2025-09-08 → Funding round, $163.0M, 2025-09-08, ○ 2026-06-02 | latest_round | seed, $163.0M, 2025-09-08 → Funding round, $163.0M, 2025-09-08 | ○ 2026-06-02 |
Records begin 2026-09-24. all_changes